

## **Dedalus, the number one provider of laboratory information systems in Europe, announces the launch of its new, flagship InVitro Suite at EuroMedLab – WorldLab 2023.**

**Milan, 2023, May 17<sup>th</sup>** – Dedalus Group ("Dedalus"), the leading healthcare and diagnostic software solutions provider in Europe, with over 30 years of experience across multiple care settings and geographies, is proud to launch its flagship, global InVitro Suite at EuroMedLab - WorldLab 2023, as part of its international expansion strategy.

The InVitro Suite, powered by a fresh brand identity, represents the pinnacle of excellence by consolidating regional knowledge, competence, and expertise into an international backbone, bringing our latest Laboratory Information System (LIS), Anatomic Pathology Information System (APIS), and Genetics Information System (GIS) to a global level. With enhanced accuracy, accelerated results, personalized medicine, and seamless collaboration, this comprehensive suite will support healthcare professionals worldwide in achieving superior outcomes for patients.

"We are proud to launch our flagship InVitro Suite, which embodies our vision, values, and commitment to excellence in the healthcare and diagnostic software solutions industry," said Marlen Suller, Head of In Vitro Diagnostics Business Unit at Dedalus. "This is a pivotal moment for Dedalus as we expand our offerings to new countries and markets. We are confident that our new brand will enable us to serve our customers better, capture new opportunities, and drive sustainable growth internationally."

The flagship InVitro Suite embodies the company's vision, values, and commitment to delivering state-of-the-art IVD software solutions for different disciplines and specialization, including clinical chemistry, microbiology, immunology, serology, haematology, anatomic pathology, genomics, and more. It prioritizes efficient and effective diagnostics, enabling full interoperability and data exchange, to meet the complex demands and high standards of the modern medical diagnostic environment.

"Our InVitro suite is in full alignment with our overall IVD product strategy, which is focused on delivering innovative, cutting-edge solutions that enable precision medicine and optimal, interdisciplinary stakeholders' decisions across the continuum of care, leveraging cloud, digital technologies, and AI to improve health outcomes," said Michael Dahlweid, MD, PhD, Chief Product & Clinical Officer at Dedalus. "We're excited to build on our success to date and look forward to introducing

our flagship InVitro Suite of solutions to even more customers worldwide."

In addition to these innovations, at EuroMedLab - WorldLab 2023, Dedalus will showcase its global IVD solutions portfolio, the gold standard in the European market, offering the full range of Clinical Pathology, Anatomic Pathology, Digital Pathology and Genetic solutions portfolio alongside the result reporting, quality assurance and Middleware software, enabling effective diagnostics in over 5700 Laboratories worldwide, and improved health outcomes across the continuum of care, for over 30 years.

To learn more, visit the Dedalus booth at EuroMedLab – WorldLab 23.

---

#### **ABOUT Dedalus**

Dedalus Group is the leading healthcare and diagnostic software provider in Europe, supporting the digital transformation of 6300 hospitals and 5700 Laboratories worldwide, processing its solutions for more than 540 millions of population worldwide. Dedalus supports the whole continuum of care, offering open standards-based solutions serving each actor of the Healthcare Ecosystem to provide better care in a healthier planet.

For more information, visit [www.Dedalus.com](http://www.Dedalus.com)

#### **CONTACT**

Dedalus SPA

Press Contact: Sara Luisa Mintrone

Tel number +39 348 2818185

sara.mintrone@Dedalus.eu

For further information:

[www.Dedalus.com](http://www.Dedalus.com)

LinkedIn : [Dedalus group](#)